Multi-scale tissue architecture analysis of favorable-risk prostate cancer: Correlation with biochemical recurrence.


Journal

Investigative and clinical urology
ISSN: 2466-054X
Titre abrégé: Investig Clin Urol
Pays: Korea (South)
ID NLM: 101674989

Informations de publication

Date de publication:
09 2020
Historique:
received: 13 01 2020
revised: 06 03 2020
accepted: 24 03 2020
pubmed: 1 8 2020
medline: 4 6 2021
entrez: 1 8 2020
Statut: ppublish

Résumé

Prostate cancer (PCa) with biopsy-based grade group (GG) 1 or 2 characteristics has a favorable outcome, yet some cases still progress after radical prostatectomy and present with biochemical recurrence (BCR). We hypothesized that the multi-scale tissue architecture (MSTA) analysis score would correlate with the aggressive PCa phenotype and could be used as a tool for risk assessment to improve the management of patients with favorable-risk PCa. MSTA was evaluated in needle-biopsy samples from 115 patients with favorable-risk PCa, as defined by GG1 and GG2, a prostate-specific antigen (PSA) level of <10 ng/mL, a clinical stage of cT1c to cT2b, and general Gleason GG (GGG) and expert pathologist-assessed GG (EGG). Algorithms based on Voronoi diagrams were applied to all Feulgen-thionin-stained diagnostic areas. One hundred tissue architecture features were calculated and an MSTA score, a linear combination of the most discriminant features, was generated. Correlation of MSTA score with BCR and other clinical variables was investigated. In a univariate regression model, EGG, clinical stage, and MSTA were significant predictors of BCR (respective p-values: 0.0016, 0.016, and 0.028). Survival analysis showed that patients with a high MSTA score were more likely to experience BCR than were patients with a low MSTA score (odds ratio, 2.9). Combining MSTA with GG assessment resulted in a significant stratification of risk for BCR. MSTA score could be used as an objective adjunct risk stratification tool to pathologist assessments and could improve the management of patients with favorable-risk PCa.

Identifiants

pubmed: 32734723
pii: 61.e43
doi: 10.4111/icu.20200018
pmc: PMC7458870
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

482-490

Informations de copyright

© The Korean Urological Association, 2020.

Déclaration de conflit d'intérêts

The authors have nothing to disclose.

Références

Anal Cell Pathol. 2000;21(2):71-86
pubmed: 11310643
Acta Histochem. 2013 Jul;115(6):527-32
pubmed: 23313439
Anal Quant Cytopathol Histpathol. 2016 Apr;38(2):59-69
pubmed: 27386626
BJU Int. 2012 Feb;109 Suppl 1:22-9
pubmed: 22239226
Anal Quant Cytol Histol. 2007 Oct;29(5):296-308
pubmed: 17987810
Comput Methods Programs Biomed. 2005 Feb;77(2):99-113
pubmed: 15652632
BJU Int. 2005 Jun;95(8):1146-52
pubmed: 15877724
Arch Pathol Lab Med. 2012 Apr;136(4):426-34
pubmed: 22458905
J Cancer Res Clin Oncol. 2008 Oct;134(10):1071-8
pubmed: 18392850
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Br J Cancer. 2017 Jul 25;117(3):367-375
pubmed: 28618431
J Natl Cancer Inst. 2010 May 5;102(9):605-13
pubmed: 20413742
Lancet Oncol. 2014 Sep;15(10):1109-18
pubmed: 25163905
Eur Urol. 2015 Jun;67(6):1168-1176
pubmed: 24996687
Cytometry A. 2017 Dec;91(12):1164-1174
pubmed: 29194951
Nat Med. 2016 Jan;22(1):105-13
pubmed: 26618723
Nat Genet. 2015 Apr;47(4):367-372
pubmed: 25730763
Oncology (Williston Park). 1997 Aug;11(8):1133-9; discussion 1139-40, 1143
pubmed: 9268976
Int Braz J Urol. 2007 Sep-Oct;33(5):639-46; discussion 647-51
pubmed: 17980061
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
IEEE Rev Biomed Eng. 2015;8:98-113
pubmed: 25055385

Auteurs

Miha Pukl (M)

Department of Urology, General Hospital Celje, Celje, Slovenia. miha.pukl@sb-celje.si.

Sarah Keyes (S)

Department of Integrative Oncology, BC Cancer, Vancouver, BC, Canada.

Mira Keyes (M)

Department of Radiation Oncology, BC Cancer, Vancouver, BC, Canada.

Martial Guillaud (M)

Department of Integrative Oncology, BC Cancer, Vancouver, BC, Canada.

Metka Volavšek (M)

Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH